UNASSIGNED: @entity1209 ( @entity1209 ) is an important clinical problem. Aprepitant is a relatively new agent for this condition which may be superior to other treatment. A systematic review was performed after searching a number of medical databases for controlled trials comparing aprepitant with conventional antiemetics published up to 25 April 2015 using the following keywords: 'Aprepitant for @entity1209 ', 'Aprepitant versus 5-HT3 antagonists' and ' @entity9766 versus 5-HT3 for @entity1209 '. The primary outcome for the pooled analysis was efficacy of aprepitant in preventing @entity391 on @entity773 . 172 potentially relevant papers were identified of which 23 had suitable data. For the primary outcome, 14 papers had relevant data. On @entity773 , 227/2341 @entity1 (9.7%) @entity1 randomised to aprepitant had a @entity391 episode compared with 496/2267 (21.9%) controls. On POD2, the rate of @entity391 among @entity1 receiving aprepitant was 6.8% compared with 12.8% for controls. The OR for @entity391 compared with controls was 0.48 (95% CI 0.34 to 0.67) on @entity773 and 0.54 (95% CI 0.40 to 0.72) on POD2. Aprepitant also demonstrated a better profile with a lower need for rescue antiemetic and a higher complete response. Efficacy for @entity391 prevention was demonstrated for 40   mg, 80   mg and 125   mg without major adverse effects. For @entity391 comparison there was significant unexplainable heterogeneity (67.9% and 71.5% for @entity773 and POD2, respectively). We conclude that (1) aprepitant reduces the incidence of @entity391 on both @entity773 and POD2, but there is an unexplained heterogeneity which lowers the strength of the evidence; (2) complete freedom from @entity1209 on @entity773 is highest for aprepitant with minimum need for rescue; and (3) oral @entity15062 (80   mg) provides an effective and safe sustained antivomiting effect.

Aprepitant for XXXX : a systematic review and meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity9766 :: ('6869', 'Gene') :: ['NK-1'] @entity773 :: ('79585', 'Gene') :: ['postoperative day (POD) 1 and 2', 'POD1'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity15062 :: ('MESH:C114556', 'Chemical') :: ['aprepitant'] @entity1209 :: ('MESH:D020250', 'Disease') :: ['Postoperative nausea and vomiting', 'PONV']
@entity1209 :: (MESH:D020250,Disease) :: ['postoperative nausea and vomiting']
